Monthly Archives: September 2016

Vanda v. Roxane Labs. – Are Two Natural Laws Better Than One?

As you will recall, in Prometheus v. Mayo, the Supreme Court held that a claim reciting a natural law had to have other non-conventional steps to pass muster under s. 101. The natural law in Mayo was the correlation between … Continue reading

Posted in Obviousness | 2 Comments

UCB v. Yeda R&D Co. – No “Safe Harbor” for Unamended Claims

UCB sued Yeda for a DJ of non-infringement of US Patent No. 6,090,923 [Appeal No. 2015-1957 (Fed. Cir. September 8, 2016)].The main claim in question was directed to “A monoclonal antibody which specifically binds a human cytotoxin [having X properties].” … Continue reading

Posted in Litigation Issues, Post-Grant Issues, Written Description Requirements (WDR) | Leave a comment

McRO v. Namco – Fed. Cir. Reverses s. 101 Invalidation of Animation Method Patents

I first posted on this case in September 2014, and urge you to find the post and the district court’s opinion in the Archives. It provides a good – well, adequate– description of the patented technology, which is a method to … Continue reading

Posted in Patent Eligible Subject Matter | Leave a comment

D. Mass Court Extends Myriad to Peptide Panels

In a great leap backwards for patenting life sciences, Magistrate Judge Cabell invalidated claims in a number of patents licensed to Oxford Immunotec that are directed to e.g., “A kit for diagnosing infection in a human host by, or exposure … Continue reading

Posted in Patent Eligible Subject Matter | Leave a comment